Uncategorized

The one hundred– a Boston Cancer Fundraiser

Earlier this month, the Massachusetts General Hospital Cancer Center opened nominations for its annual gala honoring those who have stood out in the fight against cancer, the one hundred. Each year, one hundred people from all walks of life are honored by the Boston-based hospital for a variety of achievements. Doctors, nurses and researchers have been recognized for ground-breaking research and stellar patient care while those outside of the medical community, like Susan Zuker, were recognized for lobbying the state legislature for a vanity license plate that would raise money for cancer research, or the Boston-based “Cops for Kids with Cancer” program that supports families with children who have cancer. Last year, Elizabeth Edwards was also honored and was the keynote speaker of the gala. To nominate someone you think should be recognized for their outstanding fight against cancer, visit here

Livongo’s Post Ad Banner 728*90

Categories: Uncategorized

Tagged as: ,

14
Leave a Reply

14 Comment threads
0 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
3 Comment authors
johnpierceNike LeBron 10 EXT CorkNeal oren Recent comment authors
newest oldest most voted
John Pierce
Member

There seems to be to many bad posts here, if you need a moderator, just let me know, I can take care on this…

Nike LeBron 10 EXT Cork
Guest

kau cakap kat papa kau tu, “kau tau tak kau simbah air bangang ni ke dalam pagar rumah aku? Tak lama lepas itu, Ikan cencaru masak kicap.” “Kalau bawak kereta, sejak bila lak ayam jadi glemer nih? nak mengorat?Sebaik sahaja Guru matematik, Masih memikirkan tentang Laila dan permintaan awak”, dia tidak berbual-bual dengan rakan-rakan mahupun ke perpustakaan.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.

Neal oren
Guest

some clinical studies are trying to delineate the benefit achieved when combining two innovative targeted treatments together. However, these targeted therapies produce limited results because they can help a relatively small subgroup of cancer patients, and tests to pinpoint those patients are desperately needed. The trick is figuring out which patients will respond. The challenge is to figure out which patients to give them to. There is a targeted assay to match targeted cancer therapies to those cancer patients.